Effect of COMT-inhibitor in the clinical progression of Parkinson’s disease
Objective: We conducted this 2-year follow-up study to evaluate whether or not catechol-O-methyltransferase inhibitor (COMTI) has an impact on the progression or severity of Parkinson's…Combined catechol-O-methyl-transferase inhibition and intrajejunal Levodopa infusion: A real-life single-centre experience
Objective: To explore if catechol-O-methyl-transferase inhibition (COMT-I) can prolong the efficacy of daytime intrajejunal Levodopa infusion (IJLI) in Parkinson’s disease (PD) along with a reduction…Occurrence of dopaminergic adverse-events in patients that switched from entacapone to opicapone: The BIPARK-I open-label experience
Objective: To assess the occurrence of dopaminergic adverse-events (AEs) in levodopa-treated Parkinson’s Disease (PD) patients that switched from entacapone (ENT) to opicapone (OPC) in the…Occurrence of dopaminergic adverse-events in COMT-naïve patients starting adjunctive therapy with opicapone: The BIPARK-I double-blind experience
Objective: To assess the occurrence of dopaminergic adverse-events (AEs) in levodopa-treated COMT-naïve Parkinson’s Disease (PD) patients when starting opicapone (OPC) 50mg or entacapone (ENT). Background:…Efficacy of opicapone in Parkinson’s disease patients with ‘early’ motor fluctuations: NMSS analysis from the BIPARK-I double-blind experience
Objective: To evaluate the impact on non-motor symptoms in levodopa-treated Parkinson’s Disease (PD) patients with ‘early’ motor fluctuations. Background: Opicapone (OPC), a new once-daily COMT…Switching from double-blind entacapone or placebo to open-label opicapone: NMSS results of the 1-year extension BIPARK-I study
Objective: To evaluate the impact on non-motor symptoms in levodopa-treated Parkinson’s disease (PD) patients who switched from placebo (PLC) or entacapone (ENT) to opicapone (OPC)…Efficacy of opicapone in Parkinson’s disease patients with ‘early’ motor fluctuations: UPDRS-II and III analysis from the BIPARK-I double-blind experience
Objective: To evaluate the impact on UPDRS-II and III in levodopa-treated Parkinson’s Disease (PD) patients with ‘early’ motor fluctuations. Background: Opicapone (OPC), a novel once-daily…ODM-104 and optimized carbidopa dose show beneficial effect on levodopa PK in healthy subjects
Objective: To study the dose effects of a novel catechol-O-methyl transferase (COMT) inhibitor ODM-104 and the aromatic L-amino acid decarboxylase (AADC) inhibitor carbidopa on levodopa…How to switch from Entacapone to Opicapone based on BIPARK-I study experience
Objective: To clarify how easily can entacapone (ENT) be switched to opicapone (OPC), in levodopa-treated patients with Parkinson’s disease (PD) and motor-fluctuations. Background: OPC, a…Effect of food on Opicapone pharmacokinetics and pharmacodynamics
Objective: To characterize the effect of food on the pharmacokinetics (PK) and pharmacodynamics (PD) of opicapone (OPC) after single and repeated doses. Background: OPC, a…
Abstracts from the International Congress of Parkinson’s and Movement Disorders.